PubMed

Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).

Ruggenenti P, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial Study Group.

Diabetes Care. 2008 Aug;31(8):1629-34. Epub 2008 Apr 28.PMID: 18443191 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations.

Circulation. 2003 Aug 12;108(6):684-90. Epub 2003 Jul 28.PMID: 12885747 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators.

JAMA. 2004 Nov 17;292(19):2343-9.PMID: 15547161 [PubMed - indexed for MEDLINE]Related articlesFree article

Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.

Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Jan 3;113(1):67-73. Epub 2005 Dec 19.PMID: 16365195 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.

Hypertension. 2000 Nov;36(5):766-73.PMID: 11082141 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.

JAMA. 2006 Sep 13;296(10):1242-8.PMID: 16968848 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania.

Lutale JJ, Thordarson H, Gulam-Abbas Z, Vetvik K, Gerdts E.

Cardiovasc J Afr. 2008 Jan-Feb;19(1):8-14.PMID: 18320079 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.

Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.

Ther Apher Dial. 2004 Aug;8(4):320-7.PMID: 15274684 [PubMed - indexed for MEDLINE]Related articles

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. Epub 2009 Jul 24.PMID: 19631946 [PubMed - in process]Related articles

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH; RENAAL Investigators.

Diabetologia. 2005 Oct;48(10):1980-7. Epub 2005 Aug 5.PMID: 16082528 [PubMed - indexed for MEDLINE]Related articles

Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: the Casale Monferrato Study.

Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC.

Diabet Med. 2004 Aug;21(8):823-8.PMID: 15270784 [PubMed - indexed for MEDLINE]Related articles

Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.

Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlöf B.

Am J Hypertens. 2001 Aug;14(8 Pt 1):775-82.PMID: 11497193 [PubMed - indexed for MEDLINE]Related articles

Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.

Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B; LIFE Study Group.

Hypertension. 2000 Jan;35(1 Pt 1):13-8.PMID: 10642268 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators.

Ann Intern Med. 2007 Sep 4;147(5):311-9.PMID: 17785486 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators.

Circulation. 2001 Oct 2;104(14):1615-21.PMID: 11581138 [PubMed - indexed for MEDLINE]Related articlesFree article

The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.

BENEDICT Group.

Control Clin Trials. 2003 Aug;24(4):442-61.PMID: 12865039 [PubMed - indexed for MEDLINE]Related articles

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.PMID: 16534012 [PubMed - indexed for MEDLINE]Related articlesFree article

Preventing microalbuminuria in type 2 diabetes.

Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators.

N Engl J Med. 2004 Nov 4;351(19):1941-51. Epub 2004 Oct 31.PMID: 15516697 [PubMed - indexed for MEDLINE]Related articlesFree article

Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.

Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.

Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. Epub 2008 Dec 2.PMID: 19808428 [PubMed - indexed for MEDLINE]Related articles

Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.

Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B.

J Hypertens. 2002 Jul;20(7):1445-50.PMID: 12131543 [PubMed - indexed for MEDLINE]Related articles